• We are open source synthetic biology.
    Using an open synthetic biology platform model, we rapidly prototype BactoBots and ViruBots. These applications make up our MicrobialBot portfolio. These applications are available to industry experts.

    Theses same platforms are available to responsible and capable researchers via Global SynBio and Open Therapeutics collaborative endeavors.
  • What We Do.
    Our open source synthetic biology platforms mimic natural selection. This biomimicry approach enables us to leverage millions of years of "prototyping" by natural selection. This speeds us forward in our areas of expertise: water, foods, fuels, chemicals, therapeutics, and materials.
  • Genetics Rights Management (GeRM™)
    Each MicrobialBot strain can be developed with its own unique genetics rights management (GeRM™) consumable key system. The GeRM™ system is similar to digital rights management, which is used by the software industry to protect its digital assets. GeRM™ enables us to ship our products via synthetic biology knowledge and consumable keys, instead of genetically modified organisms (GMO). In addition to protecting MicrobialBots against theft and environmental release, the GeRM™ system enables an economic development platform for creating home-grown synthetic biology industries.

    For more information about the GeRM™ value proposition, please visit our GeRM™ page.

Microbial Robotics is a global biotechnology firm.

Using open platforms, we rapidly prototype synthetic biology-based bacterial (BactoBots), viral (ViruBots), and antibiotic technologies. These MicrobialBot products are also openly available to other researchers as well as industrial water, chemical, and pharmaceutical customers.

MicrobialBots can perform functions such as induce biomarker expression by cancer cells, kill cancer cells, kill pathogens, produce chemicals, and build materials.

An Open Therapeutics™ model enables scientists and researchers to adopt our open synthetic biology platforms. These platforms enable collaborators to develop chemical, therapeutic, and water applications.

MicrobialBots can be protected by a Genetics Rights Management (GeRM™) consumable powder system. Instead of trying to ship genetically modified organisms (GMO) across borders, GeRM enables adopters to decentralize manufacturing and distribution of BactoBots and ViruBots. GeRM, as a consumable powder, creates a recurring revenue model.

Proteome Platform™ is a joint effort with Bacmine SL. Initially, this platform is focused on finding essential proteins required for pathogen survival. Discovered proteins can be targeted by researchers to develop therapeutic agents that will kill the pathogens, including antibiotic resistant organisms. Our efforts include locating potential antibiotic targets for methicillin-resistant MRSA and multi-drug resistant tuberculosis (MDR-TB).

If you are an Innovator, Researcher, or Organization, contact us today. We can help you move significant science forward, generate publications, and improve the global industrial ecosystem.